| |
Viracept (nelfinavir) Now in 625 mg Tablets: press release from Pfizer
|
| |
| |
Pfizer Inc today announced that the 625 mg formulationof the protease inhibitor, Viracept (nelfinavir mesylate) is nowavailable. Viracept, in combination with other antiretroviral agents,is indicated for the treatment of HIV infection. Pfizer is bringing thevalue of the new Viracept 625 mg formulation to the marketplace at noadditional cost to the patient.
The VIRACEPT 625 mg formulation will be availablethrough retail and mail order pharmacies as well as institutionalsuppliers after June 1, 2004.
The new dosage enables patients to take two pillstwice a day instead of five pills twice a day on the previous 250 mgformulation. This will lighten the pill burden for HIV patients.VIRACEPT should be taken with a meal. VIRACEPT is three to five timesmore likely to get into the blood stream when taken with a meal, whencompared to fasting. In healthy volunteers receiving a single 1,250 mgdose, the 625 mg tablet demonstrated greater bioavailability than the250 mg tablet formulation under fasted or fed conditions.
VIRACEPT has been shown to be generally well tolerated. The mostfrequently reported adverse event among patients receiving VIRACEPT wasdiarrhea, which was generally of mild to moderate intensity. Thefrequency of VIRACEPT-associated diarrhea may be increased in patientsreceiving the 625 mg tablet. Redistribution/accumulation of body fathas been reported in patients receiving antiretroviral therapy. Acausal relationship has not been established and long-term consequencesare not known at this time. Full prescribing information is availableat www.viracept.com .
Patients currently taking 250 mg tablets of VIRACEPTshould talk to their health care providers to determine if switching toVIRACEPT 625 mg is appropriate for them.
Health care professionals can call 1-888-VIRACEPT for more informationabout where to order the VIRACEPT 625 mg formulation or for additionalproduct information.
|
|
| |
| |
|
|
|
